IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma

Bulletin Express

03/30

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).

IMM0306 Profile • Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20. • Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally. • Mode of Action: – Blocks the CD47-SIRPα “don’t eat me” signal, enhancing macrophage-mediated phagocytosis. – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells. – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity. • Rights: The Group holds global intellectual property and commercial rights to IMM0306.

Regulatory Note In accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.

The announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1177793692"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177793692\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177793692?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 22:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177793692","market":"us","top_or_hot":-1,"title":"IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma","media":"Bulletin Express","content":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).</p>\n<p>IMM0306 Profile  \n• Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20.  \n• Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally.  \n• Mode of Action:  \n  – Blocks the CD47-SIRPα “don’t eat me” signal, enhancing macrophage-mediated phagocytosis.  \n  – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells.  \n  – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity.  \n• Rights: The Group holds global intellectual property and commercial rights to IMM0306.</p>\n<p>Regulatory Note  \nIn accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.</p>\n<p>The announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-30 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).</p>\n<p>IMM0306 Profile  \n• Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20.  \n• Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally.  \n• Mode of Action:  \n  – Blocks the CD47-SIRPα “don’t eat me” signal, enhancing macrophage-mediated phagocytosis.  \n  – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells.  \n  – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity.  \n• Rights: The Group holds global intellectual property and commercial rights to IMM0306.</p>\n<p>Regulatory Note  \nIn accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.</p>\n<p>The announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"","article_id":"1177793692","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177793692","pubTimestamp":1774882102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B"},"translate_title":"IMMUNEONCO-B启动III期研究：首例接受双重靶向疗法IMM0306治疗复发/难治性滤泡性淋巴瘤的患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (R/R FL).\nIMM0306 Profile  \n• Mechanism: A bispecific molecule simultaneously targeting CD47 and CD20.  \n• Clinical Milestone: First CD47/CD20 dual-targeting bispecific therapy to reach the clinical stage globally.  \n• Mode of Action:  \n  – Blocks the CD47-SIRPα 「don’t eat me」 signal, enhancing macrophage-mediated phagocytosis.  \n  – Strengthens Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells.  \n  – Prefers CD20 over CD47 binding, aiming to eliminate malignant B cells while minimizing toxicity.  \n• Rights: The Group holds global intellectual property and commercial rights to IMM0306.\nRegulatory Note  \nIn accordance with Rule 18A.05 of the Hong Kong Listing Rules, IMMUNEONCO-B cautions that successful development and commercialization of IMM0306 are not guaranteed.\nThe announcement was authorized by Chairman and Executive Director Dr. Tian Wenzhi on 30 March 2026 in Shanghai.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}